Clinical trial
A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Treatment in Genotype 1 HCV Infected Patients Resistant to Pegylated Interferon-alpha and Ribavirin
NCT01024894 is registered in ClinicalTrials.gov with Cytheris SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Treatment in Genotype 1 HCV Infected Patients Resistant to Pegylated Interferon-alpha and Ribavirin
- Lead sponsor
- Cytheris SA
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- January 31, 2009
- Completion date
- December 31, 2012
- Enrollment
- 15 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.